<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Hum Mol Genet</journal-id><journal-id journal-id-type="publisher-id">hmg</journal-id><journal-id journal-id-type="hwp">hmg</journal-id><journal-title-group><journal-title>Human Molecular Genetics</journal-title></journal-title-group><issn pub-type="ppub">0964-6906</issn><issn pub-type="epub">1460-2083</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1093/hmg/ddp264</article-id><article-id pub-id-type="publisher-id">ddp264</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Correction of tau mis-splicing caused by FTDP-17 <italic>MAPT</italic> mutations by spliceosome-mediated RNA <italic>trans-</italic>splicing</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rodriguez-Martin</surname><given-names>Teresa</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Anthony</surname><given-names>Karen</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Garcia-Blanco</surname><given-names>Mariano A.</given-names></name><xref ref-type="aff" rid="af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Mansfield</surname><given-names>S. Gary</given-names></name><xref ref-type="aff" rid="af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Anderton</surname><given-names>Brian H.</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gallo</surname><given-names>Jean-Marc</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="af1"><label>1</label><addr-line>MRC Centre for Neurodegeneration Research, Department of Clinical Neuroscience, King's College London</addr-line>, <institution>Institute of Psychiatry</institution>, <addr-line>De Crespigny Park, London SE5 8AF</addr-line>, <country>UK</country></aff><aff id="af2"><label>2</label><addr-line>MRC Centre for Neurodegeneration Research</addr-line>, <institution>Department of Neuroscience, King's College London, Institute of Psychiatry, De Crespigny Park, London SE5 8AF</institution>, <country>UK</country></aff><aff id="af3"><label>3</label><addr-line>Center for RNA Biology, Department of Molecular Genetics and Microbiology</addr-line>, <institution>Duke University Medical Center</institution>, <addr-line>Durham, NC 27710</addr-line>, <country>USA</country></aff><aff id="af4"><label>4</label><institution>VIRxSYS Inc.</institution>, <addr-line>200 Perry Parkway, Gaithersburg, MD 20877</addr-line>, <country>USA</country></aff><author-notes><corresp id="cor1"><label>*</label>To whom correspondence should be addressed at: <addr-line>MRC Centre for Neurodegeneration Research, Department of Clinical Neuroscience, King's College London</addr-line><institution>Institute of Psychiatry</institution>, <addr-line>Box PO37, De Crespigny Park, London SE5 8AF</addr-line>, <country>UK</country>. Tel: <phone>+44 207 848 0404</phone>; Fax: <fax>+44 207 708 0017</fax>; Email: <email>jean-marc.gallo@kcl.ac.uk</email></corresp></author-notes><pub-date pub-type="ppub"><day>1</day><month>9</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>4</day><month>6</month><year>2009</year></pub-date><pub-date pub-type="pmc-release"><day>4</day><month>6</month><year>2009</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>18</volume><issue>17</issue><fpage>3266</fpage><lpage>3273</lpage><history><date date-type="received"><day>5</day><month>5</month><year>2009</year></date><date date-type="rev-recd"><day>5</day><month>5</month><year>2009</year></date><date date-type="accepted"><day>1</day><month>6</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; 2009 The Author(s)</copyright-statement><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/uk/"><license-p><!--CREATIVE COMMONS-->This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/uk/">http://creativecommons.org/licenses/by-nc/2.0/uk/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) is caused by mutations in the <italic>MAPT</italic> gene, encoding the tau protein that accumulates in intraneuronal lesions in a number of neurodegenerative diseases. Several FTDP-17 mutations affect alternative splicing and result in excess exon 10 (E10) inclusion in tau mRNA. RNA reprogramming using spliceosome-mediated RNA <italic>trans</italic>-splicing (SMaRT) could be a method of choice to correct aberrant E10 splicing resulting from FTDP-17 mutations. SMaRT creates a hybrid mRNA through a <italic>trans-</italic>splicing reaction between an endogenous target pre-mRNA and a pre-<italic>trans-</italic>splicing RNA molecule (PTM). However, FTDP-17 mutations affect the strength of <italic>cis</italic>-splicing elements and could favor <italic>cis</italic>-splicing over <italic>trans</italic>-splicing. Excess E10 inclusion in FTDP-17 can be caused by intronic mutations destabilizing a stem-loop protecting the 5&#x02032; splice site at the E10/intron 10 junction. COS cells transfected with a minigene containing the intronic +14 mutation produce exclusively E10<sup>+</sup> RNA. Generation of E10<sup>&#x02212;</sup> RNA was restored after co-transfection with a PTM designed to exclude E10. Similar results were obtained with a target containing the exonic N279K mutation which strengthens a splicing enhancer within E10. Conversely, increase or decrease in E10 content was achieved by <italic>trans-</italic>splicing from a target carrying the &#x00394;280K mutation, which weakens the same splicing enhancer. Thus E10 inclusion can be modulated by <italic>trans</italic>-splicing irrespective of the strength of the <italic>cis</italic>-splicing elements affected by FTDP-17 mutations. In conclusion, RNA <italic>trans-</italic>splicing could provide the basis of therapeutic strategies for impaired alternative splicing caused by pathogenic mutations in <italic>cis-</italic>acting splicing elements.</p></abstract></article-meta></front><body><sec id="s1"><title>INTRODUCTION</title><p>Tauopathies are major diseases of the central nervous system characterized neuropathologically by intracellular filamentous inclusions formed by the microtubule-associated protein tau in affected neurons (<xref ref-type="bibr" rid="DDP264C1">1</xref>,<xref ref-type="bibr" rid="DDP264C2">2</xref>). Tauopathies include dementias such as Alzheimer's disease and some forms of frontotemporal dementia (<xref ref-type="bibr" rid="DDP264C3">3</xref>). Definitive evidence for the pathogenic importance of tau was provided by the discovery of dominant mutations in the <italic>MAPT</italic> gene, the gene encoding tau, in the rare dementia, frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) (<xref ref-type="bibr" rid="DDP264C4">4</xref>&#x02013;<xref ref-type="bibr" rid="DDP264C6">6</xref>).</p><p>The <italic>MAPT</italic> gene comprises 16 exons and alternative splicing of exons 2, 3 and 10 generates six isoforms in the brain. Exon 10 (E10) encodes the second of four imperfect 31&#x02013;32 amino-acid microtubule-binding repeats in the C-terminal half of the protein. Exclusion or inclusion of E10 generate tau isoforms with three (3R tau, E10<sup>&#x02212;</sup>) or four (4R tau, E10<sup>+</sup>) microtubule-binding repeats, the latter having an increased affinity for microtubules. E10 is expressed only in adults and E10<sup>+</sup> and E10<sup>&#x02212;</sup> isoforms are expressed in approximately equal amounts in adult human brain.</p><p>To date, more than thirty-five <italic>MAPT</italic> mutations have been associated with FTDP-17. Most missense mutations reduce the affinity of tau for microtubules (<xref ref-type="bibr" rid="DDP264C7">7</xref>), whereas silent or intronic mutations affect E10 splicing and can result in an up to 6-fold excess of tau mRNA containing E10 and in an elevated 4R/3R ratio (<xref ref-type="bibr" rid="DDP264C4">4</xref>,<xref ref-type="bibr" rid="DDP264C6">6</xref>,<xref ref-type="bibr" rid="DDP264C8">8</xref>,<xref ref-type="bibr" rid="DDP264C9">9</xref>). Elevated 4R/3R ratio is likely to have functional consequences, for example in the regulation of axonal transport (<xref ref-type="bibr" rid="DDP264C10">10</xref>).</p><p>From a therapeutic perspective, correcting defective alternative splicing is best achieved by direct intervention at the RNA level. RNA can be reprogrammed by using spliceosome-mediated RNA <italic>trans-</italic>splicing (SMaRT<sup>&#x000ae;</sup>) (<xref ref-type="bibr" rid="DDP264C11">11</xref>). SMaRT creates a hybrid mRNA through a <italic>trans-</italic>splicing reaction mediated by the spliceosome between the 5&#x02032; splice site of an endogenous target pre-mRNA and the 3&#x02032; splice site of an exogenously delivered pre-<italic>trans-</italic>splicing RNA molecule (PTM). Conversely, a PTM can be designed to carry the 5&#x02032; splice site and <italic>trans-</italic>splice to the 3&#x02032; splice site of a specific target (<xref ref-type="bibr" rid="DDP264C12">12</xref>). A typical application of SMaRT is the correction of loss-of-function mutations. We have shown previously that E10<sup>&#x02212;</sup> to E10<sup>+</sup> tau RNA conversion could be achieved using SMaRT (<xref ref-type="bibr" rid="DDP264C13">13</xref>). Thus, SMaRT could be a method of choice to correct aberrant E10 splicing resulting from FTDP-17 mutations. However, FTDP-17 mutations affect the strength of <italic>cis</italic>-splicing elements and could favor <italic>cis</italic>-splicing over <italic>trans</italic>-splicing. For instance, most intronic mutations are clustered at the exon 10-intron 10 junction and disrupt a stem-loop structure protecting the 5&#x02032; splice site (<xref ref-type="bibr" rid="DDP264C14">14</xref>,<xref ref-type="bibr" rid="DDP264C15">15</xref>). Furthermore, with the exception of the P301L/S mutations, mutations within E10 are located in <italic>cis-</italic>acting splicing regulatory elements and promote E10 retention (<xref ref-type="bibr" rid="DDP264C16">16</xref>,<xref ref-type="bibr" rid="DDP264C17">17</xref>). We therefore addressed the question of the potential effectiveness of SMaRT to correct aberrant E10 splicing caused by FTDP-17 mutations. Here we show that elevated or reduced E10 inclusion caused by intronic or exonic FTDP-17 mutations can be reversed by <italic>trans</italic>-splicing. Hence, RNA <italic>trans-</italic>splicing could provide the basis for the development of promising therapeutic strategies for impaired alternative splicing, especially in the context of neurological diseases.</p></sec><sec id="s2"><title>RESULTS</title><sec id="s2a"><title>Tau PTM constructs</title><p>We have shown previously that E10 could be introduced in tau RNA by SMaRT (13). We have now designed a PTM, TauPTM9, to exclude E10. TauPTM9 comprises a binding domain hybridizing with the 3&#x02032; end of intron 9 and human tau exons 11&#x02013;13 followed by a FLAG epitope sequence in the coding sequence (Fig.&#x000a0;<xref ref-type="fig" rid="DDP264F1">1</xref>). COS cells were co-transfected with TauPTM9 and the LI9/LI10 tau minigene consisting of the full genomic <italic>MAPT</italic> sequence from exon 9 to exon 11, including exons 9, 10, 11 and the entire introns 9 and 10 (<xref ref-type="bibr" rid="DDP264C18">18</xref>). As a positive control, cells were also co-transfected with the minigene and TauPTM6, designed to introduce E10 in tau RNA (<xref ref-type="bibr" rid="DDP264C13">13</xref>). To detect <italic>trans-</italic>spliced products, RNA was analyzed by RT&#x02013;PCR with a minigene-specific forward primer, VctF, corresponding to a pCIneo vector sequence, and the PTM-specific reverse primer, FLAGR, complementary to the FLAG epitope sequence. Using this primer combination, a product of 773 bp was detected in cells transfected with TauPTM9 (Fig.&#x000a0;<xref ref-type="fig" rid="DDP264F2">2</xref>A). <italic>Trans</italic>-splicing was also detected in cells transfected with the minigene and TauPTM6, that has the same binding and <italic>trans</italic>-splicing domains as TauPTM9. The 93 bp difference in size between the TauPTM6 (866 bp) and TauPTM9 products correspond to E10 (Fig.&#x000a0;<xref ref-type="fig" rid="DDP264F2">2</xref>A). Sequencing of VctF-FLAGR products confirmed that exact exon 9&#x02013;exon 10 and exon 9&#x02013;exon 11 junctions had been generated using TauPTM6 and TauPTM9, respectively, and demonstrates that <italic>trans-</italic>splicing has occurred between minigene transcripts and either PTM.</p><fig id="DDP264F1" position="float"><label>Figure&#x000a0;1.</label><caption><p>Structure of TauPTM6 and TauPTM9 and resulting <italic>trans-</italic>spliced products. The coding sequence of TauPTM6 and TauPTM9 consists of exons 10&#x02013;13 or exons 11&#x02013;13, respectively, followed by a 24 nt FLAG epitope sequence. The <italic>trans-</italic>splicing domain of the PTMs comprises a 125 nt binding domain (BD) complementary to the 3&#x02032; end of tau intron 9 as well as a strong conserved yeast branch point sequence (BP), a 26 nt polypyrimidine tract (PPT), an AG acceptor site and a spacer sequence separating the binding domain and the branch point. Arrows indicate the locations of the PCR primers used to detect <italic>cis</italic>- and <italic>trans</italic>-splicing events.</p></caption><graphic xlink:href="ddp26401"/></fig><fig id="DDP264F2" position="float"><label>Figure&#x000a0;2.</label><caption><p><italic>Trans-</italic>splicing modulation of E10 usage in tau transcripts. COS cells were co-transfected with the LI9/LI10 minigene and TauPTM6 or TauPTM9. (<bold>A</bold>) RT&#x02013;PCR analysis with the forward primer VctF, specific for the target minigene and the PTM-specific reverse primer FLAGR, complementary to the FLAG epitope sequence, demonstrates <italic>trans-</italic>splicing between minigene transcripts and PTMs. The difference in size between the products generated using Tau PTM6 and TauPTM9 corresponds to E10. (<bold>B</bold>) Change in E10 inclusion after co-transfection of LI9/LI10 with TauPTM6 and TauPTM9. Both <italic>cis-</italic> and <italic>trans-</italic>spliced products were detected by RT&#x02013;PCR with the forward primer VctF and the reverse primer 11R, corresponding to an exon 11 sequence. Co-transfection with TauPTM6 or TauPTM9 resulted in an increase or decrease of E10 inclusion, respectively.</p></caption><graphic xlink:href="ddp26402"/></fig><p>We next analyzed whether <italic>trans</italic>-splicing with TauPTM9 was accompanied by a reduction in E10 inclusion in the total mature RNA (i.e. <italic>cis-</italic>spliced and <italic>trans-</italic>spliced) derived from LI9/LI10. Reverse transcribed RNA was amplified with the VctF primer, as above, and the reverse primer 11R complementary to an exon 11 sequence, that detects both <italic>cis</italic>- and <italic>trans</italic>-spliced products. Co-transfection of LI9/LI10 with TauPTM9 resulted in a decrease in E10 inclusion (Fig.&#x000a0;<xref ref-type="fig" rid="DDP264F2">2</xref>B). Conversely, and as reported previously (<xref ref-type="bibr" rid="DDP264C13">13</xref>), co-transfection with TauPTM6 resulted in increased E10 inclusion (Fig.&#x000a0;<xref ref-type="fig" rid="DDP264F2">2</xref>B). These results show that E10 usage can be modulated in either direction, irrespective of the <italic>cis</italic>-splicing fate on an individual targeted pre-mRNA.</p></sec><sec id="s2b"><title><italic>Trans</italic>-splicing reduction of E10 excess caused by intronic <italic>MAPT</italic> mutations</title><p>FTDP-17 <italic>MAPT</italic> mutations affecting splicing are located in splicing regulatory elements and most produce excess E10 inclusion. We assessed whether the level of E10 inclusion in tau RNA could be reduced by <italic>trans-</italic>splicing in the context of FTDP-17 mutations. As mutations are within or close to E10, <italic>trans</italic>-splicing assays with mutant targets were performed using the TauEx9-11<sup>WT</sup> minigene backbone, with minimal intronic sequences flanking E10 (<xref ref-type="bibr" rid="DDP264C19">19</xref>) (Fig.&#x000a0;<xref ref-type="fig" rid="DDP264F3">3</xref>A). The sequence of the exon 10/intron 10 junction predicts a stem-loop structure regulating E10 splicing by protecting the 5&#x02032; splice site. FTDP-17 mutations +3 to +16 destabilize the stem loop and enhance E10 inclusion (<xref ref-type="bibr" rid="DDP264C14">14</xref>,<xref ref-type="bibr" rid="DDP264C15">15</xref>,<xref ref-type="bibr" rid="DDP264C19">19</xref>). Among these the +14 DDPAC mutation is one of the most potent at increasing E10 inclusion (<xref ref-type="bibr" rid="DDP264C4">4</xref>). To confirm that the +14 mutation resulted in E10 excess in mature tau RNA, tau splicing was compared between COS cells transfected with the wild-type minigene, TauEx9-11<sup>WT</sup> or the TauEx9-11<sup>DDPAC</sup> minigene, containing the +14 mutation. TauEx9-11<sup>WT</sup> generated mostly E10<sup>+</sup> RNA with a small amount of E10<sup>&#x02212;</sup> RNA (Fig.&#x000a0;<xref ref-type="fig" rid="DDP264F3">3</xref>B). In contrast, the TauEx9-11<sup>DDPAC</sup> minigene produced exclusively E10<sup>+</sup> RNA (Fig.&#x000a0;<xref ref-type="fig" rid="DDP264F3">3</xref>B).</p><fig id="DDP264F3" position="float"><label>Figure&#x000a0;3.</label><caption><p>Splicing pattern of minigenes containing FTDP-17 mutations. (<bold>A</bold>) Structure of the <italic>MAPT</italic> minigenes incorporating the exonic N279K and &#x00394;280K mutations or the intronic DDPAC +14 mutation. The backbone minigene, TauEx9-11, consists of tau exons 9&#x02013;10&#x02013;11 and 498 bp 5&#x02032; and 264 bp 3&#x02032; of intronic sequences flanking E10. (<bold>B</bold>) Splicing was assayed by RT&#x02013;PCR using primers VctF and 11R in transfected COS cells. TauEx9-11<sup>WT</sup> produces mainly E10<sup>+</sup> RNA; the mutants minigenes, TauEx9-11<sup>DDPAC</sup> and TauEx9-11<sup>N279K</sup>, produce exclusively E10<sup>+</sup> RNA, whereas TauEx9-11<sup>&#x00394;280K</sup> produces an excess of E10<sup>&#x02212;</sup> RNA. Arrows indicate the locations of the PCR primers used to detect splice isoforms.</p></caption><graphic xlink:href="ddp26403"/></fig><p>To determine whether RNA lacking E10 could be generated by <italic>trans</italic>-splicing from a target containing the +14 mutation COS cells were co-transfected with the TauEx9-11<sup>DDPAC</sup> minigene and TauPTM9 and analyzed for occurrence of <italic>trans-</italic>splicing and levels of E10 inclusion using the VctF-FLAGR or VctF-11R primer combinations. <italic>Trans</italic>-splicing was first confirmed for the wild-type minigene, TauEx9-11<sup>WT</sup>, and Tau PTM6 or TauPTM9 (Fig.&#x000a0;<xref ref-type="fig" rid="DDP264F4">4</xref>A, B). Analysis of cells co-transfected with the TauEx9-11<sup>DDPAC</sup> minigene and TauPTM6 or TauPTM9 demonstrated <italic>trans-</italic>splicing between transcripts from the minigene and either PTM (Fig.&#x000a0;<xref ref-type="fig" rid="DDP264F4">4</xref>C). In the absence of PTM, the TauEx9-11<sup>DDPAC</sup> minigene produced E10<sup>+</sup> RNA only. In contrast, products lacking E10 were generated in cells co-transfected with TauPTM9 (Fig.&#x000a0;<xref ref-type="fig" rid="DDP264F4">4</xref>D). Based on the reduction in the percentage of E10 inclusion estimated by semi-quantitative PCR, restoration of E10<sup>&#x02212;</sup> RNA was achieved with a &#x0223c;11% efficiency. The generation of E10<sup>&#x02212;</sup> RNA is not the consequence of a direct change in <italic>cis-</italic>splicing activity secondary to the blocking of a potential splicing enhancer in intron 9 by the binding of the PTM as such products were not observed with TauPTM6 which has the same binding domain as TauPTM9 (Fig.&#x000a0;<xref ref-type="fig" rid="DDP264F4">4</xref>D).</p><fig id="DDP264F4" position="float"><label>Figure&#x000a0;4.</label><caption><p><italic>Trans-</italic>splicing reduction of E10 inclusion in tau transcripts with the intronic +14 mutation. COS cells were co-transfected with a wild-type tau minigene, TauEx9-11<sup>WT</sup> (<bold>A</bold> and <bold>B</bold>) or the TauEx9-11<sup>DDPAC</sup> minigene containing the +14 mutation (<bold>C</bold> and <bold>D</bold>) and TauPTM6 or TauPTM9 and analyzed by RT&#x02013;PCR. (A and C) PCR analysis with primers VctF and FLAGR demonstrates <italic>trans-</italic>splicing between minigene transcripts and PTMs. (B and D) E10 usage after co-transfection with the minigenes was analyzed by RT&#x02013;PCR using the VctF&#x02013;11R primer combination. (B) Co-transfection of TauEx9-11<sup>WT</sup> with TauPTM9 reduced E10 inclusion. (D) The TauEx9-11<sup>DDPAC</sup> minigene produces E10<sup>+</sup> RNA only and E10<sup>&#x02212;</sup> products were generated after co-transfection with TauPTM9. Co-transfection with TauPTM6 had no effect on E10 inclusion.</p></caption><graphic xlink:href="ddp26404"/></fig><p>To exclude the possibility that the hybrid RNA observed was the result of recombination events at the DNA level between minigene and PTM PCR analysis was conducted with or without reverse transcription and with an extension time sufficient to amplify potential recombination products. No <italic>trans-</italic>splicing (Fig.&#x000a0;<xref ref-type="fig" rid="DDP264F5">5</xref>A) or <italic>cis-</italic> and <italic>trans-</italic>splicing (Fig.&#x000a0;<xref ref-type="fig" rid="DDP264F5">5</xref>B) products were detected when the reverse transcription step was omitted. In addition, no large size species that would have been indicative of recombination were amplified from the traces of DNA present in the RNA preparation using the VctF-FLAGR primer combination (Fig.&#x000a0;<xref ref-type="fig" rid="DDP264F5">5</xref>A). In contrast minigene DNA was readily detected using the VctF-11R primer combination (Fig.&#x000a0;<xref ref-type="fig" rid="DDP264F5">5</xref>B). Therefore E10 can be skipped by <italic>trans</italic>-splicing in the presence of a constitutively available 5&#x02032; splice site in the target.</p><fig id="DDP264F5" position="float"><label>Figure&#x000a0;5.</label><caption><p>Absence of recombination between minigene and PTM at the DNA level. RNA isolated from cells co-transfected with TauEx9-11<sup>DDPAC</sup> and TauPTM6 or TauPTM9 was analyzed by PCR with (+RT) or without (&#x02212;RT) prior reverse transcription. No <italic>cis-</italic> or <italic>trans-</italic>splicing (<bold>A</bold> and <bold>B</bold>) products were detected without RT. (A) <italic>Trans-</italic>splicing products only are amplified using the VctF-FLAGR primer combination; no larger size species were detected with or without RT. (B) In contrast, in addition to <italic>cis-</italic> and <italic>trans-</italic>splicing products, minigene DNA was readily amplified from the traces of DNA present in the RNA preparation using the VctF&#x02013;11R primer combination.</p></caption><graphic xlink:href="ddp26405"/></fig></sec><sec id="s2c"><title><italic>Trans-</italic>splicing reduction of E10 excess caused by exonic <italic>MAPT</italic> mutations</title><p>The N279K mutation is located within an exonic splicing enhancer (ESE) in E10, and increases E10 inclusion by facilitating the use of the 3&#x02032; splice site of intron 9 (<xref ref-type="bibr" rid="DDP264C16">16</xref>,<xref ref-type="bibr" rid="DDP264C20">20</xref>). In transfected cells, a minigene carrying the N279K mutation, TauEx9-11<sup>N279K</sup>, produces exclusively E10<sup>+</sup> RNA (Fig.&#x000a0;<xref ref-type="fig" rid="DDP264F3">3</xref>B). COS cells were co-transfected with the TauEx9-11<sup>N279K</sup> minigene and analyzed for occurrence of <italic>trans-</italic>splicing and levels of E10 inclusion, as earlier. Analysis with the VctF and FLAGR primers demonstrated <italic>trans-</italic>splicing between transcripts from the TauEx9-11<sup>N279K</sup> minigene and both TauPTM6 and Tau PTM9 (Fig.&#x000a0;<xref ref-type="fig" rid="DDP264F6">6</xref>A). Co-transfection of TauEx9-11<sup>N279K</sup> with TauPTM9 resulted in the appearance of E10<sup>&#x02212;</sup> products with a &#x0223c;7% efficiency, whereas co-transfection with TauPTM6 had no effect (Fig.&#x000a0;<xref ref-type="fig" rid="DDP264F6">6</xref>B).</p><fig id="DDP264F6" position="float"><label>Figure&#x000a0;6.</label><caption><p><italic>Trans-</italic>splicing modulation of E10 usage in tau transcripts with the exonic N279K and &#x00394;280K mutations. COS cells were co-transfected with the TauEx9-11<sup>N279K</sup> (<bold>A</bold> and <bold>B</bold>) or the TauEx9-11<sup>&#x00394;280K</sup> (<bold>C</bold> and <bold>D</bold>) tau minigenes and TauPTM6 or TauPTM9 and analyzed by RT&#x02013;PCR. (A and C) PCR analysis with primers VctF&#x02013;FLAGR demonstrates <italic>trans-</italic>splicing between minigene transcripts and PTMs. (B and D) E10 usage after co-transfection with the minigenes was analyzed by RT&#x02013;PCR using the VctF-11R primer combination. (B) Co-transfection of TauEx9-11<sup>N279K</sup> with TauPTM9 resulted in the appearance of E10<sup>&#x02212;</sup> products. Co-transfection with TauPTM6 had no effect on E10 inclusion. (D) The TauEx9-11<sup>&#x00394;280K</sup> minigene produces both E10<sup>+</sup> and E10<sup>&#x02212;</sup> RNA, with a slight excess of E10<sup>&#x02212;</sup> RNA. Co-transfection with TauPTM6 or TauPTM9 increased or reduced E10 inclusion, respectively.</p></caption><graphic xlink:href="ddp26406"/></fig><p>The ESE strengthened by the N279 mutation is weakened by the &#x00394;280K deletion, causing reduced E10 inclusion (<xref ref-type="bibr" rid="DDP264C16">16</xref>). In transfected cells, an excess of E10<sup>&#x02212;</sup> RNA is produced from a minigene containing the &#x00394;280K mutation, TauEx9-11<sup>&#x00394;280K</sup> (Fig.&#x000a0;<xref ref-type="fig" rid="DDP264F3">3</xref>B). RT&#x02013;PCR analysis demonstrated <italic>trans-</italic>splicing between TauEx9-11<sup>&#x00394;280K</sup> transcripts and either TauPTM6 or Tau PTM9 and a resulting increase or decrease in the level of E10 inclusion, respectively (Fig.&#x000a0;<xref ref-type="fig" rid="DDP264F6">6</xref>C, D). Taken together, these results show that E10 usage can be modulated by <italic>trans</italic>-splicing independently of the strength of the <italic>cis</italic>-regulatory elements in the targets.</p></sec></sec><sec id="s3"><title>DISCUSSION</title><p>In this study, we have demonstrated that aberrant tau E10 splicing resulting from FTDP-17 mutations can be partially corrected by <italic>trans</italic>-splicing. We showed previously that <italic>cis-</italic>splicing exclusion of E10 could be by-passed by <italic>trans-</italic>splicing and that E10<sup>&#x02212;</sup> to E10<sup>+</sup> tau RNA conversion could be achieved from wild-type tau sequences (<xref ref-type="bibr" rid="DDP264C13">13</xref>). The demonstration that E10 inclusion can be reduced as well as increased by <italic>trans-</italic>splicing shows that <italic>trans</italic>-splicing can occur irrespective of the outcome of the <italic>cis</italic>-splicing event determined by the combination of splicing factors recruited by an individual pre-mRNA. Importantly, correction of aberrant splicing caused by FTDP-17 mutations shows that <italic>trans</italic>-splicing can be achieved in the presence of <italic>cis</italic>-splicing elements of altered strength.</p><p>Most intronic FTDP-17 mutations are clustered at the exon 10&#x02013;intron 10 junction. This region is predicted to form a stem-loop structure regulating E10 splicing by protecting the 5&#x02032; splice site. FTDP-17 mutations +3 to +16, as well as the exonic S305N mutation, destabilize the stem loop making the 5&#x02032; splice site of intron 10 constitutively available, hence promoting E10 inclusion (<xref ref-type="bibr" rid="DDP264C14">14</xref>,<xref ref-type="bibr" rid="DDP264C15">15</xref>,<xref ref-type="bibr" rid="DDP264C20">20</xref>). E10 retention results in a 1.5- to 6-fold increase in the E10<sup>+</sup>/E10<sup>&#x02212;</sup> ratio (<xref ref-type="bibr" rid="DDP264C4">4</xref>,<xref ref-type="bibr" rid="DDP264C9">9</xref>). <italic>Trans-</italic>splicing was achieved using a target carrying the very potent DDPAC +14 mutation and produced mature RNA lacking E10 demonstrating that the constitutive availability of the 5&#x02032; splice site of intron 10 does not interfere with <italic>trans-</italic>splicing.</p><p>The N279K mutation, within E10, strengthens an ESE and facilitates the use of the 3&#x02032; splice site of intron 9. The affinity of the splicing factors, Tra2&#x003b2; and SF2/ASF, for the ESE is enhanced by the N279K mutation and, conversely, Tra2&#x003b2; and SF2/ASF affinity for the ESE is reduced by the &#x00394;280K deletion (<xref ref-type="bibr" rid="DDP264C16">16</xref>,<xref ref-type="bibr" rid="DDP264C17">17</xref>,<xref ref-type="bibr" rid="DDP264C21">21</xref>). The &#x00394;280K mutation is the only known <italic>MAPT</italic> mutation that reduces E10 inclusion and is associated with lesions containing exclusively, or, at least predominantly, 3R tau (<xref ref-type="bibr" rid="DDP264C22">22</xref>,<xref ref-type="bibr" rid="DDP264C23">23</xref>). <italic>Trans</italic>-splicing obtained with the N279K mutation and subsequent production of RNA lacking E10 shows that enhanced availability of the 3&#x02032; splice site of intron 9 in the target does not interfere with the use of the 3&#x02032; splice site from the PTM, which is required for the <italic>trans</italic>-splicing reaction. Therefore abnormal binding of Tra2&#x003b2; and/or SF2/ASF to the ESE within the target does not inhibit <italic>trans-</italic>splicing modulation of E10 usage in either direction. However, its efficiency might be influenced by the interplay between <italic>trans-</italic>acting factors recruited on the target and on the PTM.</p><p>The possibility of correcting E10 inclusion is relevant not only for FTDP-17 but also for sporadic tauopathies. A single molecule analysis of tau isoforms in Alzheimer's disease brain revealed an increase to 1.3 in the E10<sup>+</sup>/E10<sup>&#x02212;</sup> ratio (<xref ref-type="bibr" rid="DDP264C24">24</xref>). In addition, the H1 haplotype of the <italic>MAPT</italic> gene, which is associated with an increased risk of Alzheimer's disease, expresses more E10<sup>+</sup> tau mRNA than the H2 haplotype (<xref ref-type="bibr" rid="DDP264C25">25</xref>,<xref ref-type="bibr" rid="DDP264C26">26</xref>).</p><p>Several chemical inhibitors of E10 inclusion have been identified through high throughput screening and could provide drug leads (<xref ref-type="bibr" rid="DDP264C27">27</xref>,<xref ref-type="bibr" rid="DDP264C28">28</xref>). However, RNA-based therapies are gaining increasing popularity due to their specificity and versatility (<xref ref-type="bibr" rid="DDP264C29">29</xref>). Among those, SMaRT has proved to be a very powerful method to correct loss-of-function mutations at the RNA level (<xref ref-type="bibr" rid="DDP264C30">30</xref>&#x02013;<xref ref-type="bibr" rid="DDP264C33">33</xref>). Recent applications have included correction of &#x003b2;-globin in sickle-cell anemia and &#x003b2;-thalassemia (<xref ref-type="bibr" rid="DDP264C34">34</xref>), plectin (PLEC1) in blistering skin disease epidermolysis bullosa simplex with muscular dystrophy (EBS-MD) (<xref ref-type="bibr" rid="DDP264C35">35</xref>), severe combined immune deficiency (SCID) (<xref ref-type="bibr" rid="DDP264C36">36</xref>), spinal muscular atrophy (<xref ref-type="bibr" rid="DDP264C37">37</xref>,<xref ref-type="bibr" rid="DDP264C38">38</xref>) and myotonic dystrophy (<xref ref-type="bibr" rid="DDP264C39">39</xref>). Gene therapy for brain diseases is still at an early stage, but several classes of viral vectors have been developed for the transduction of neurons (<xref ref-type="bibr" rid="DDP264C40">40</xref>,<xref ref-type="bibr" rid="DDP264C41">41</xref>). Furthermore, long-term expression of <italic>trans-</italic>splicing molecules obtained using viral vectors or transposon systems has been shown to result in recovery of functional defects compatible with a therapeutic benefit (<xref ref-type="bibr" rid="DDP264C36">36</xref>,<xref ref-type="bibr" rid="DDP264C38">38</xref>,<xref ref-type="bibr" rid="DDP264C42">42</xref>&#x02013;<xref ref-type="bibr" rid="DDP264C44">44</xref>). The level of tau E10 splicing correction necessary for a detectable phenotypic effect is not known, neither is the precise consequence of tau isoform imbalance on microtubule properties and functions or on neurotoxicity. <italic>Trans-</italic>splicing reduction of E10 inclusion on endogenous tau could be optimized in induced pluripotent stem cells derived from FTDP-17 patients, when available, after differentiation into neurons (<xref ref-type="bibr" rid="DDP264C45">45</xref>).</p><p>An increasing number of neurological and other disorders are being associated with aberrant alternative splicing (<xref ref-type="bibr" rid="DDP264C46">46</xref>&#x02013;<xref ref-type="bibr" rid="DDP264C49">49</xref>) and SMaRT would be an approach to be developed to correct aberrant splicing caused by pathogenic mutations in <italic>cis-</italic>acting splicing elements.</p></sec><sec id="s4" sec-type="methods"><title>MATERIALS AND METHODS</title><sec id="s4a"><title>Pre-<italic>trans-</italic>splicing molecules</title><p>The pre-<italic>trans-</italic>splicing molecule, TauPTM6, in the mammalian expression vector, pcDNA3.1, has been described previously (<xref ref-type="bibr" rid="DDP264C13">13</xref>). TauPTM6 is designed to include E10 in tau RNA; its coding sequence consists of tau exons 10&#x02013;13, followed by a FLAG epitope sequence (5&#x02032;-GACTACAAGGACGACGATGACAAG-3&#x02032;). TauPTM9, designed to exclude E10 from tau RNA, was generated by deleting E10 from TauPTM6, using restriction digestions and ligation of synthetic oligonucleotides.</p></sec><sec id="s4b"><title>Tau minigene targets</title><p>The LI9/LI10 minigene in the pCIneo vector comprises tau exons 9&#x02013;10&#x02013;11 and full-length introns 9 and 10 (<xref ref-type="bibr" rid="DDP264C18">18</xref>) and was obtained from Dr Jianhua Zhou (University of Massachusetts Medical School, Worcester). Minigenes TauEx9-11<sup>WT</sup> and TauEx9-11<sup>DDPAC</sup> comprising tau exons 9&#x02013;10&#x02013;11 and 498 bp of 5&#x02032; and 264 bp 3&#x02032; of intronic sequences flanking E10 (<xref ref-type="bibr" rid="DDP264C19">19</xref>) (Fig.&#x000a0;<xref ref-type="fig" rid="DDP264F3">3</xref>) were obtained from Dr Jane Wu (Northwestern University Feinberg School of Medicine, Chicago). The TauEx9-11<sup>DDPAC</sup> minigene carries the intronic +14 DDPAC FTDP-17 mutation. Two additional minigenes, TauEx9-11<sup>N279K</sup> and TauEx9-11<sup>&#x00394;280K</sup> were constructed by introducing the exonic N279K and &#x00394;280K mutations into TauEx9-11 using the Quick-Change site-directed mutagenesis kit (Stratagene). Wild-type and mutant minigenes based on TauEx9-11 were subcloned into pCIneo. All constructs were verified by sequencing.</p></sec><sec id="s4c"><title>Cell culture and transfection</title><p>COS-7 cells were maintained in DMEM supplemented with 10% (v/v) heat inactivated FBS (Invitrogen), 100 U/ml penicillin/100 &#x000b5;g/ml streptomycin and 2 m<sc>m</sc><sc>l</sc>-glutamine, in a humidified atmosphere of 95% air/5% CO<sub>2</sub> at 37&#x000b0;C. Cells were transfected with Lipofectamine 2000 reagent (Invitrogen). Briefly, cells plated on 35 mm dishes were grown to 60&#x02013;70% confluency and exposed to the DNA/liposome complex for 5 h in Optimem (Invitrogen) before being returned to normal culture medium. Cells were routinely analyzed 24 h after transfection. Cells were transfected with either tau minigene plus empty vector or PTM plus empty vector, or co-transfected with minigene and PTM. Typically, 2 &#x000b5;g minigene and 2 &#x000b5;g PTM were used in each transfection.</p></sec><sec id="s4d"><title>RT&#x02013;PCR analysis of <italic>cis-</italic> and <italic>trans-</italic>splicing</title><p>Total RNA was isolated from transfected cells using Trizol reagent (Invitrogen). Reverse transcription was performed using the Multiscribe&#x02122; RT kit (Applied Biosystem) and oligo-(dT)<sub>16</sub>. Reverse transcription was carried out under the following conditions: 10 min at 25&#x000b0;C, 30 min at 48&#x000b0;C and a final step of 5 min at 95&#x000b0;C. Reverse transcribed RNA was amplified by using Go <italic>Taq</italic> polymerase (Promega) under the following conditions: 94&#x000b0;C for 5 min, 30 cycles of 1 min at 94&#x000b0;C, 1 min at 58&#x000b0;C, 1 min at 72&#x000b0;C and a final step of 10 min at 72&#x000b0;C. An extension time of 3 min was used in reactions designed to visualize DNA. The sequence of the primers used for PCR and the sizes of <italic>cis-</italic> and <italic>trans-</italic>splicing products are listed in Table&#x000a0;<xref ref-type="table" rid="DDP264TB1">1</xref>. PCR products were separated by electrophoresis in 2% (w/v) agarose gels and stained with ethidium bromide. Densitometric analysis of triplicate experiments was performed using the Innotech software (Alpha Innotech, San Leandro, CA, USA). Splicing activity was expressed as percentage of E10 inclusion. The efficiency of E10<sup>+</sup> to E10<sup>&#x02212;</sup> conversion was estimated from the percentage of E10 inclusion in cells transfected with minigene only (p<sub>1</sub>) and co-transfected with minigene and PTM (p<sub>2</sub>) as 100 &#x000d7; (p<sub>1</sub>&#x02212;p<sub>2</sub>)/p<sub>1</sub>. For sequencing, PCR products were excised from agarose gels and cloned into the pCR2.1 vector using the TA cloning system (Invitrogen). Sequencing of both strands was performed using T3 and T7 primers.</p><table-wrap id="DDP264TB1" position="float"><label>Table&#x000a0;1.</label><caption><p>Sequence of the PCR primers used to detect <italic>cis-</italic> and <italic>trans-</italic>splicing products and sizes of the corresponding products</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Name</th><th align="left" rowspan="1" colspan="1">Location</th><th align="left" rowspan="1" colspan="1">Sequence</th><th align="left" rowspan="1" colspan="1">Product size</th></tr></thead><tbody><tr><td rowspan="2" colspan="1"><italic>Cis-</italic> and <italic>trans-</italic>splicing</td><td rowspan="1" colspan="1">VctF</td><td rowspan="1" colspan="1">Vector</td><td rowspan="1" colspan="1">5&#x02032;-GGTGTCCACTCCCAGTTCAA</td><td rowspan="1" colspan="1">E10+518 bp</td></tr><tr><td rowspan="1" colspan="1">11R</td><td rowspan="1" colspan="1">Exon 11</td><td rowspan="1" colspan="1">5&#x02032;-CCCTGGTTTATGATGGATGTTGCCTAATGAG</td><td rowspan="1" colspan="1">E10- 425 bp</td></tr><tr><td rowspan="2" colspan="1"><italic>Trans</italic>-splicing</td><td rowspan="1" colspan="1">VctF</td><td rowspan="1" colspan="1">Vector</td><td rowspan="1" colspan="1">5&#x02032;-GGTGTCCACTCCCAGTTCAA</td><td rowspan="1" colspan="1">E10+866 bp</td></tr><tr><td rowspan="1" colspan="1">FLAGR</td><td rowspan="1" colspan="1">FLAG sequence</td><td rowspan="1" colspan="1">5&#x02032;-TTGTCATCGTCGTCCTTGTAG</td><td rowspan="1" colspan="1">E10- 773 bp</td></tr></tbody></table><table-wrap-foot><fn><p>The forward primer, VctF, corresponds to a sequence in the pCIneo vector and is specific for the target minigenes. The FLAGR reverse primer, complementary to a FLAG epitope sequence, is specific for PTMs and was used to demonstrate <italic>trans-</italic>splicing. The reverse primer 11R is complementary to an exon 11 sequence and detects both <italic>cis-</italic> and <italic>trans-</italic>spliced products.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s5"><title>FUNDING</title><p>This work was supported by the <funding-source>Wellcome Trust</funding-source>, the <funding-source>Biotechnology and Biological Sciences Research Council</funding-source>, <funding-source>the Medical Research Council</funding-source>, <funding-source>Ataxia UK, the Alzheimer's Research Trust</funding-source> and <funding-source>the Psychiatry Research Trust</funding-source>. Funding to pay the Open Access publication charges for this article was provided by the Wellcome Trust.</p></sec></body><back><ack><title>ACKNOWLEDGEMENTS</title><p>We thank Drs Jianhua Zhou and Jane Wu for tau minigenes.</p><p><italic>Conflict of Interest statement</italic>. M.A.G.-B. is a founder of Intronn, a company that was set up for the development and commercialization of the SMaRT technology. Intronn has been bought by VIRxSYS and M.G.-B. is a consultant for VIRxSYS. S.G.M. is an employee of VIRxSYS.</p></ack><ref-list><title>REFERENCES</title><ref id="DDP264C1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballatore</surname><given-names>C.</given-names></name><name><surname>Lee</surname><given-names>V.M.</given-names></name><name><surname>Trojanowski</surname><given-names>J.Q.</given-names></name></person-group><article-title>Tau-mediated neurodegeneration in Alzheimer's disease and related disorders</article-title><source>Nat. Rev. Neurosci.</source><year>2007</year><volume>8</volume><fpage>663</fpage><lpage>672</lpage><pub-id pub-id-type="pmid">17684513</pub-id></element-citation></ref><ref id="DDP264C2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallo</surname><given-names>J.-M.</given-names></name><name><surname>Noble</surname><given-names>W.</given-names></name><name><surname>Rodriguez Martin</surname><given-names>T.</given-names></name></person-group><article-title>RNA and protein-dependent mechanisms in tauopathies: consequences for therapeutic strategies</article-title><source>Cell. Mol. Life Sci.</source><year>2007</year><volume>64</volume><fpage>1701</fpage><lpage>1714</lpage><pub-id pub-id-type="pmid">17453144</pub-id></element-citation></ref><ref id="DDP264C3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>D.R.</given-names></name></person-group><article-title>Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau</article-title><source>Intern. Med. J.</source><year>2006</year><volume>36</volume><fpage>652</fpage><lpage>660</lpage><pub-id pub-id-type="pmid">16958643</pub-id></element-citation></ref><ref id="DDP264C4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutton</surname><given-names>M.</given-names></name><name><surname>Lendon</surname><given-names>C.L.</given-names></name><name><surname>Rizzu</surname><given-names>P.</given-names></name><name><surname>Baker</surname><given-names>M.</given-names></name><name><surname>Froelich</surname><given-names>S.</given-names></name><name><surname>Houlden</surname><given-names>H.H.</given-names></name><name><surname>Pickering Brown</surname><given-names>S.</given-names></name><name><surname>Chakraverty</surname><given-names>S.</given-names></name><name><surname>Isaacs</surname><given-names>A.</given-names></name><name><surname>Grover</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Association of missense and 5&#x02032;-splice-site mutations in tau with the inherited dementia FTDP-17</article-title><source>Nature</source><year>1998</year><volume>393</volume><fpage>702</fpage><lpage>704</lpage><pub-id pub-id-type="pmid">9641683</pub-id></element-citation></ref><ref id="DDP264C5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poorkaj</surname><given-names>P.</given-names></name><name><surname>Bird</surname><given-names>T.D.</given-names></name><name><surname>Wijsman</surname><given-names>E.</given-names></name><name><surname>Nemens</surname><given-names>E.</given-names></name><name><surname>Garruto</surname><given-names>R.M.</given-names></name><name><surname>Anderson</surname><given-names>L.</given-names></name><name><surname>Andreadis</surname><given-names>A.</given-names></name><name><surname>Wiederholt</surname><given-names>W.C.</given-names></name><name><surname>Raskind</surname><given-names>M.</given-names></name><name><surname>Schellenberg</surname><given-names>G.D.</given-names></name></person-group><article-title>Tau is a candidate gene for chromosome 17 frontotemporal dementia</article-title><source>Ann. Neurol</source><year>1998</year><volume>43</volume><fpage>815</fpage><lpage>825</lpage><pub-id pub-id-type="pmid">9629852</pub-id></element-citation></ref><ref id="DDP264C6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spillantini</surname><given-names>M.G.</given-names></name><name><surname>Murrell</surname><given-names>J.R.</given-names></name><name><surname>Goedert</surname><given-names>M.</given-names></name><name><surname>Farlow</surname><given-names>M.R.</given-names></name><name><surname>Klug</surname><given-names>A.</given-names></name><name><surname>Ghetti</surname><given-names>B.</given-names></name></person-group><article-title>Mutation in the tau gene in familial multiple system tauopathy with presenile dementia</article-title><source>Proc. Natl Acad. Sci. USA</source><year>1998</year><volume>95</volume><fpage>7737</fpage><lpage>7741</lpage><pub-id pub-id-type="pmid">9636220</pub-id></element-citation></ref><ref id="DDP264C7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandt</surname><given-names>R.</given-names></name><name><surname>Hundelt</surname><given-names>M.</given-names></name><name><surname>Shahani</surname><given-names>N.</given-names></name></person-group><article-title>Tau alteration and neuronal degeneration in tauopathies: mechanisms and models</article-title><source>Biochim. Biophys. Acta.</source><year>2005</year><volume>1739</volume><fpage>331</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">15615650</pub-id></element-citation></ref><ref id="DDP264C8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>M.</given-names></name><name><surname>Zhukareva</surname><given-names>V.</given-names></name><name><surname>Vogelsberg-Ragaglia</surname><given-names>V.</given-names></name><name><surname>Wszolek</surname><given-names>Z.</given-names></name><name><surname>Reed</surname><given-names>L.</given-names></name><name><surname>Miller</surname><given-names>B.I.</given-names></name><name><surname>Geschwind</surname><given-names>D.H.</given-names></name><name><surname>Bird</surname><given-names>T.D.</given-names></name><name><surname>McKeel</surname><given-names>D.</given-names></name><name><surname>Goate</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17</article-title><source>Science</source><year>1998</year><volume>282</volume><fpage>1914</fpage><lpage>1917</lpage><pub-id pub-id-type="pmid">9836646</pub-id></element-citation></ref><ref id="DDP264C9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Connell</surname><given-names>J.W.</given-names></name><name><surname>Rodriguez-Martin</surname><given-names>T.</given-names></name><name><surname>Gibb</surname><given-names>G.M.</given-names></name><name><surname>Khan</surname><given-names>N.M.</given-names></name><name><surname>Grierson</surname><given-names>A.J.</given-names></name><name><surname>Hanger</surname><given-names>D.P.</given-names></name><name><surname>Revesz</surname><given-names>T.</given-names></name><name><surname>Anderton</surname><given-names>B.H.</given-names></name><name><surname>Gallo</surname><given-names>J.-M.</given-names></name></person-group><article-title>Quantitative analysis of tau isoform transcripts in sporadic tauopathies</article-title><source>Brain Res. Mol. Brain Res.</source><year>2005</year><volume>137</volume><fpage>104</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">15950767</pub-id></element-citation></ref><ref id="DDP264C10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dixit</surname><given-names>R.</given-names></name><name><surname>Ross</surname><given-names>J.L.</given-names></name><name><surname>Goldman</surname><given-names>Y.E.</given-names></name><name><surname>Holzbaur</surname><given-names>E.L.</given-names></name></person-group><article-title>Differential regulation of dynein and kinesin motor proteins by tau</article-title><source>Science</source><year>2008</year><volume>319</volume><fpage>1086</fpage><lpage>1089</lpage><pub-id pub-id-type="pmid">18202255</pub-id></element-citation></ref><ref id="DDP264C11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puttaraju</surname><given-names>M.</given-names></name><name><surname>Jamison</surname><given-names>S.F.</given-names></name><name><surname>Mansfield</surname><given-names>S.G.</given-names></name><name><surname>Garcia-Blanco</surname><given-names>M.A.</given-names></name><name><surname>Mitchell</surname><given-names>L.G.</given-names></name></person-group><article-title>Spliceosome-mediated RNA <italic>trans</italic>-splicing as a tool for gene therapy</article-title><source>Nat. Biotechnol.</source><year>1999</year><volume>17</volume><fpage>246</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">10096291</pub-id></element-citation></ref><ref id="DDP264C12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansfield</surname><given-names>S.G.</given-names></name><name><surname>Clark</surname><given-names>R.H.</given-names></name><name><surname>Puttaraju</surname><given-names>M.</given-names></name><name><surname>Kole</surname><given-names>J.</given-names></name><name><surname>Cohn</surname><given-names>J.A.</given-names></name><name><surname>Mitchell</surname><given-names>L.G.</given-names></name><name><surname>Garcia-Blanco</surname><given-names>M.A.</given-names></name></person-group><article-title>5&#x02032; exon replacement and repair by spliceosome-mediated RNA <italic>trans</italic>-splicing</article-title><source>RNA</source><year>2003</year><volume>9</volume><fpage>1290</fpage><lpage>1297</lpage><pub-id pub-id-type="pmid">13130143</pub-id></element-citation></ref><ref id="DDP264C13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Martin</surname><given-names>T.</given-names></name><name><surname>Garcia-Blanco</surname><given-names>M.A.</given-names></name><name><surname>Mansfield</surname><given-names>S.G.</given-names></name><name><surname>Grover</surname><given-names>A.C.</given-names></name><name><surname>Hutton</surname><given-names>M.</given-names></name><name><surname>Yu</surname><given-names>Q.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Anderton</surname><given-names>B.H.</given-names></name><name><surname>Gallo</surname><given-names>J.-M.</given-names></name></person-group><article-title>Reprogramming of tau alternative splicing by spliceosome-mediated RNA <italic>trans</italic>-splicing: Implications for tauopathies</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2005</year><volume>102</volume><fpage>15659</fpage><lpage>15664</lpage><pub-id pub-id-type="pmid">16230627</pub-id></element-citation></ref><ref id="DDP264C14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grover</surname><given-names>A.</given-names></name><name><surname>Houlden</surname><given-names>H.</given-names></name><name><surname>Baker</surname><given-names>M.</given-names></name><name><surname>Adamson</surname><given-names>J.</given-names></name><name><surname>Lewis</surname><given-names>J.</given-names></name><name><surname>Prihar</surname><given-names>G.</given-names></name><name><surname>Pickering-Brown</surname><given-names>S.</given-names></name><name><surname>Duff</surname><given-names>K.</given-names></name><name><surname>Hutton</surname><given-names>M.</given-names></name></person-group><article-title>5&#x02032; splice site mutations in tau associated with the inherited dementia FTDP-17 affect a stem-loop structure that regulates alternative splicing of exon 10</article-title><source>J. Biol. Chem.</source><year>1999</year><volume>274</volume><fpage>15134</fpage><lpage>15143</lpage><pub-id pub-id-type="pmid">10329720</pub-id></element-citation></ref><ref id="DDP264C15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donahue</surname><given-names>C.P.</given-names></name><name><surname>Muratore</surname><given-names>C.</given-names></name><name><surname>Wu</surname><given-names>J.Y.</given-names></name><name><surname>Kosik</surname><given-names>K.S.</given-names></name><name><surname>Wolfe</surname><given-names>M.S.</given-names></name></person-group><article-title>Stabilization of the tau exon 10 stem loop alters pre-mRNA splicing</article-title><source>J. Biol. Chem.</source><year>2006</year><volume>281</volume><fpage>23302</fpage><lpage>23306</lpage><pub-id pub-id-type="pmid">16782711</pub-id></element-citation></ref><ref id="DDP264C16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Souza</surname><given-names>I.</given-names></name><name><surname>Poorkaj</surname><given-names>P.</given-names></name><name><surname>Hong</surname><given-names>M.</given-names></name><name><surname>Nochlin</surname><given-names>D.</given-names></name><name><surname>Lee</surname><given-names>V.M.</given-names></name><name><surname>Bird</surname><given-names>T.D.</given-names></name><name><surname>Schellenberg</surname><given-names>G.D.</given-names></name></person-group><article-title>Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements</article-title><source>Proc. Natl Acad. Sci. USA</source><year>1999</year><volume>96</volume><fpage>5598</fpage><lpage>5603</lpage><pub-id pub-id-type="pmid">10318930</pub-id></element-citation></ref><ref id="DDP264C17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Z.</given-names></name><name><surname>Tang</surname><given-names>H.</given-names></name><name><surname>Havlioglu</surname><given-names>N.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Stamm</surname><given-names>S.</given-names></name><name><surname>Yan</surname><given-names>R.</given-names></name><name><surname>Wu</surname><given-names>J.Y.</given-names></name></person-group><article-title>Mutations in tau gene exon 10 associated with FTDP-17 alter the activity of an exonic splicing enhancer to interact with Tra2&#x003b2;</article-title><source>J. Biol. Chem.</source><year>2003</year><volume>278</volume><fpage>18997</fpage><lpage>19007</lpage><pub-id pub-id-type="pmid">12649279</pub-id></element-citation></ref><ref id="DDP264C18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Q.</given-names></name><name><surname>Guo</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name></person-group><article-title>A minimal length between tau exon 10 and 11 is required for correct splicing of exon 10</article-title><source>J. Neurochem.</source><year>2004</year><volume>90</volume><fpage>164</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">15198676</pub-id></element-citation></ref><ref id="DDP264C19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Z.</given-names></name><name><surname>Cote</surname><given-names>J.</given-names></name><name><surname>Kwon</surname><given-names>J.M.</given-names></name><name><surname>Goate</surname><given-names>A.M.</given-names></name><name><surname>Wu</surname><given-names>J.Y.</given-names></name></person-group><article-title>Aberrant splicing of tau pre-mRNA caused by intronic mutations associated with the inherited dementia frontotemporal dementia with parkinsonism linked to chromosome 17</article-title><source>Mol. Cell Biol.</source><year>2000</year><volume>20</volume><fpage>4036</fpage><lpage>4048</lpage><pub-id pub-id-type="pmid">10805746</pub-id></element-citation></ref><ref id="DDP264C20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasegawa</surname><given-names>M.</given-names></name><name><surname>Smith</surname><given-names>M.J.</given-names></name><name><surname>Iijima</surname><given-names>M.</given-names></name><name><surname>Tabira</surname><given-names>T.</given-names></name><name><surname>Goedert</surname><given-names>M.</given-names></name></person-group><article-title>FTDP-17 mutations N279K and S305N in tau produce increased splicing of exon 10</article-title><source>FEBS Lett.</source><year>1999</year><volume>443</volume><fpage>93</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">9989582</pub-id></element-citation></ref><ref id="DDP264C21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Souza</surname><given-names>I.</given-names></name><name><surname>Schellenberg</surname><given-names>G.D.</given-names></name></person-group><article-title>Arginine/serine-rich protein interaction domain-dependent modulation of a tau exon 10 splicing enhancer: altered interactions and mechanisms for functionally antagonistic FTDP-17 mutations &#x00394;280K and N279K</article-title><source>J. Biol. Chem.</source><year>2006</year><volume>281</volume><fpage>2460</fpage><lpage>2469</lpage><pub-id pub-id-type="pmid">16308321</pub-id></element-citation></ref><ref id="DDP264C22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Swieten</surname><given-names>J.C.</given-names></name><name><surname>Bronner</surname><given-names>I.F.</given-names></name><name><surname>Azmani</surname><given-names>A.</given-names></name><name><surname>Severijnen</surname><given-names>L.A.</given-names></name><name><surname>Kamphorst</surname><given-names>W.</given-names></name><name><surname>Ravid</surname><given-names>R.</given-names></name><name><surname>Rizzu</surname><given-names>P.</given-names></name><name><surname>Willemsen</surname><given-names>R.</given-names></name><name><surname>Heutink</surname><given-names>P.</given-names></name></person-group><article-title>The &#x00394;K280 mutation in MAP tau favors exon 10 skipping <italic>in vivo</italic></article-title><source>J. Neuropathol. Exp. Neurol.</source><year>2007</year><volume>66</volume><fpage>17</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">17204933</pub-id></element-citation></ref><ref id="DDP264C23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Momeni</surname><given-names>P.</given-names></name><name><surname>Pittman</surname><given-names>A.</given-names></name><name><surname>Lashley</surname><given-names>T.</given-names></name><name><surname>Vandrovcova</surname><given-names>J.</given-names></name><name><surname>Malzer</surname><given-names>E.</given-names></name><name><surname>Luk</surname><given-names>C.</given-names></name><name><surname>Hulette</surname><given-names>C.</given-names></name><name><surname>Lees</surname><given-names>A.</given-names></name><name><surname>Revesz</surname><given-names>T.</given-names></name><name><surname>Hardy</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Clinical and pathological features of an Alzheimer's disease patient with the <italic>MAPT</italic> &#x00394;K280 mutation</article-title><source>Neurobiol. Aging</source><year>2009</year><volume>30</volume><fpage>388</fpage><lpage>393</lpage><pub-id pub-id-type="pmid">17723255</pub-id></element-citation></ref><ref id="DDP264C24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conrad</surname><given-names>C.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Conrad</surname><given-names>C.</given-names></name><name><surname>Schoenfeld</surname><given-names>D.</given-names></name><name><surname>Fang</surname><given-names>Z.</given-names></name><name><surname>Ingelsson</surname><given-names>M.</given-names></name><name><surname>Stamm</surname><given-names>S.</given-names></name><name><surname>Church</surname><given-names>G.</given-names></name><name><surname>Hyman</surname><given-names>B.T.</given-names></name></person-group><article-title>Single molecule profiling of tau gene expression in Alzheimer's disease</article-title><source>J. Neurochem.</source><year>2007</year><volume>103</volume><fpage>1228</fpage><lpage>1236</lpage><pub-id pub-id-type="pmid">17727636</pub-id></element-citation></ref><ref id="DDP264C25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caffrey</surname><given-names>T.M.</given-names></name><name><surname>Joachim</surname><given-names>C.</given-names></name><name><surname>Paracchini</surname><given-names>S.</given-names></name><name><surname>Esiri</surname><given-names>M.M.</given-names></name><name><surname>Wade-Martins</surname><given-names>R.</given-names></name></person-group><article-title>Haplotype-specific expression of exon 10 at the human <italic>MAPT</italic> locus</article-title><source>Hum. Mol. Genet.</source><year>2006</year><volume>15</volume><fpage>3529</fpage><lpage>3537</lpage><pub-id pub-id-type="pmid">17085483</pub-id></element-citation></ref><ref id="DDP264C26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myers</surname><given-names>A.J.</given-names></name><name><surname>Pittman</surname><given-names>A.M.</given-names></name><name><surname>Zhao</surname><given-names>A.S.</given-names></name><name><surname>Rohrer</surname><given-names>K.</given-names></name><name><surname>Kaleem</surname><given-names>M.</given-names></name><name><surname>Marlowe</surname><given-names>L.</given-names></name><name><surname>Lees</surname><given-names>A.</given-names></name><name><surname>Leung</surname><given-names>D.</given-names></name><name><surname>McKeith</surname><given-names>I.G.</given-names></name><name><surname>Perry</surname><given-names>R.H.</given-names></name><etal/></person-group><article-title>The <italic>MAPT</italic> H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts</article-title><source>Neurobiol. Dis.</source><year>2006</year><volume>25</volume><fpage>561</fpage><lpage>570</lpage><pub-id pub-id-type="pmid">17174556</pub-id></element-citation></ref><ref id="DDP264C27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donahue</surname><given-names>C.P.</given-names></name><name><surname>Ni</surname><given-names>J.</given-names></name><name><surname>Rozners</surname><given-names>E.</given-names></name><name><surname>Glicksman</surname><given-names>M.A.</given-names></name><name><surname>Wolfe</surname><given-names>M.S.</given-names></name></person-group><article-title>Identification of tau stem loop RNA stabilizers</article-title><source>J. Biomol. Screen.</source><year>2007</year><volume>12</volume><fpage>789</fpage><lpage>799</lpage><pub-id pub-id-type="pmid">17525136</pub-id></element-citation></ref><ref id="DDP264C28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoilov</surname><given-names>P.</given-names></name><name><surname>Lin</surname><given-names>C.H.</given-names></name><name><surname>Damoiseaux</surname><given-names>R.</given-names></name><name><surname>Nikolic</surname><given-names>J.</given-names></name><name><surname>Black</surname><given-names>D.L.</given-names></name></person-group><article-title>A high-throughput screening strategy identifies cardiotonic steroids as alternative splicing modulators</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2008</year><volume>105</volume><fpage>11218</fpage><lpage>11223</lpage><pub-id pub-id-type="pmid">18678901</pub-id></element-citation></ref><ref id="DDP264C29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>M.</given-names></name><name><surname>Yin</surname><given-names>H.</given-names></name><name><surname>McClorey</surname><given-names>G.</given-names></name></person-group><article-title>Modulating the expression of disease genes with RNA-based therapy</article-title><source>PLoS. Genet.</source><year>2007</year><volume>3</volume><fpage>e109</fpage><pub-id pub-id-type="pmid">17604456</pub-id></element-citation></ref><ref id="DDP264C30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Blanco</surname><given-names>M.A.</given-names></name></person-group><article-title>Messenger RNA reprogramming by spliceosome-mediated RNA <italic>trans</italic>-splicing</article-title><source>J. Clin. Invest.</source><year>2003</year><volume>112</volume><fpage>474</fpage><lpage>480</lpage><pub-id pub-id-type="pmid">12925685</pub-id></element-citation></ref><ref id="DDP264C31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansfield</surname><given-names>S.G.</given-names></name><name><surname>Chao</surname><given-names>H.</given-names></name><name><surname>Walsh</surname><given-names>C.E.</given-names></name></person-group><article-title>RNA repair using spliceosome-mediated RNA <italic>trans</italic>-splicing</article-title><source>Trends Mol. Med.</source><year>2004</year><volume>10</volume><fpage>263</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">15177190</pub-id></element-citation></ref><ref id="DDP264C32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Walsh</surname><given-names>C.E.</given-names></name></person-group><article-title>Spliceosome-mediated RNA <italic>trans</italic>-splicing</article-title><source>Mol. Ther.</source><year>2005</year><volume>12</volume><fpage>1006</fpage><lpage>1012</lpage><pub-id pub-id-type="pmid">16226059</pub-id></element-citation></ref><ref id="DDP264C33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>L.G.</given-names></name><name><surname>McGarrity</surname><given-names>G.J.</given-names></name></person-group><article-title>Gene therapy progress and prospects: reprograming gene expression by <italic>trans</italic>-splicing</article-title><source>Gene Ther.</source><year>2005</year><volume>12</volume><fpage>1477</fpage><lpage>1485</lpage><pub-id pub-id-type="pmid">16121205</pub-id></element-citation></ref><ref id="DDP264C34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kierlin-Duncan</surname><given-names>M.N.</given-names></name><name><surname>Sullenger</surname><given-names>B.A.</given-names></name></person-group><article-title>Using 5&#x02032;-PTMs to repair mutant &#x003b2;-globin transcripts</article-title><source>RNA</source><year>2007</year><volume>13</volume><fpage>1317</fpage><lpage>1327</lpage><pub-id pub-id-type="pmid">17556711</pub-id></element-citation></ref><ref id="DDP264C35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wally</surname><given-names>V.</given-names></name><name><surname>Klausegger</surname><given-names>A.</given-names></name><name><surname>Koller</surname><given-names>U.</given-names></name><name><surname>Lochmuller</surname><given-names>H.</given-names></name><name><surname>Krause</surname><given-names>S.</given-names></name><name><surname>Wiche</surname><given-names>G.</given-names></name><name><surname>Mitchell</surname><given-names>L.G.</given-names></name><name><surname>Hintner</surname><given-names>H.</given-names></name><name><surname>Bauer</surname><given-names>J.W.</given-names></name></person-group><article-title>5&#x02032; <italic>trans</italic>-splicing repair of the PLEC1 gene</article-title><source>J. Invest Dermatol.</source><year>2008</year><volume>128</volume><fpage>568</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">17989727</pub-id></element-citation></ref><ref id="DDP264C36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zayed</surname><given-names>H.</given-names></name><name><surname>Xia</surname><given-names>L.</given-names></name><name><surname>Yerich</surname><given-names>A.</given-names></name><name><surname>Yant</surname><given-names>S.R.</given-names></name><name><surname>Kay</surname><given-names>M.A.</given-names></name><name><surname>Puttaraju</surname><given-names>M.</given-names></name><name><surname>McGarrity</surname><given-names>G.J.</given-names></name><name><surname>Wiest</surname><given-names>D.L.</given-names></name><name><surname>McIvor</surname><given-names>R.S.</given-names></name><name><surname>Tolar</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Correction of DNA protein kinase deficiency by spliceosome-mediated RNA trans-splicing and Sleeping Beauty transposon delivery</article-title><source>Mol. Ther.</source><year>2007</year><volume>15</volume><fpage>1273</fpage><lpage>1279</lpage><pub-id pub-id-type="pmid">17457319</pub-id></element-citation></ref><ref id="DDP264C37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coady</surname><given-names>T.H.</given-names></name><name><surname>Shababi</surname><given-names>M.</given-names></name><name><surname>Tullis</surname><given-names>G.E.</given-names></name><name><surname>Lorson</surname><given-names>C.L.</given-names></name></person-group><article-title>Restoration of SMN function: Delivery of a <italic>trans</italic>-splicing RNA re-directs SMN2 pre-mRNA splicing</article-title><source>Mol. Ther.</source><year>2007</year><volume>15</volume><fpage>1471</fpage><lpage>1478</lpage><pub-id pub-id-type="pmid">17551501</pub-id></element-citation></ref><ref id="DDP264C38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coady</surname><given-names>T.H.</given-names></name><name><surname>Baughan</surname><given-names>T.D.</given-names></name><name><surname>Shababi</surname><given-names>M.</given-names></name><name><surname>Passini</surname><given-names>M.A.</given-names></name><name><surname>Lorson</surname><given-names>C.L.</given-names></name></person-group><article-title>Development of a single vector system that enhances <italic>trans</italic>-splicing of <italic>SMN2</italic> transcripts</article-title><source>PLoS. ONE.</source><year>2008</year><volume>3</volume><fpage>e3468</fpage><pub-id pub-id-type="pmid">18941511</pub-id></element-citation></ref><ref id="DDP264C39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H.Y.</given-names></name><name><surname>Kathirvel</surname><given-names>P.</given-names></name><name><surname>Yee</surname><given-names>W.C.</given-names></name><name><surname>Lai</surname><given-names>P.S.</given-names></name></person-group><article-title>Correction of dystrophia myotonica type 1 pre-mRNA transcripts by artificial <italic>trans</italic>-splicing</article-title><source>Gene Ther.</source><year>2009</year><volume>16</volume><fpage>211</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">18923454</pub-id></element-citation></ref><ref id="DDP264C40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azzouz</surname><given-names>M.</given-names></name><name><surname>Kingsman</surname><given-names>S.M.</given-names></name><name><surname>Mazarakis</surname><given-names>N.D.</given-names></name></person-group><article-title>Lentiviral vectors for treating and modeling human CNS disorders</article-title><source>J. Gene Med.</source><year>2004</year><volume>6</volume><fpage>951</fpage><lpage>962</lpage><pub-id pub-id-type="pmid">15352068</pub-id></element-citation></ref><ref id="DDP264C41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>L.F.</given-names></name><name><surname>Azzouz</surname><given-names>M.</given-names></name><name><surname>Walmsley</surname><given-names>L.E.</given-names></name><name><surname>Askham</surname><given-names>Z.</given-names></name><name><surname>Wilkes</surname><given-names>F.J.</given-names></name><name><surname>Mitrophanous</surname><given-names>K.A.</given-names></name><name><surname>Kingsman</surname><given-names>S.M.</given-names></name><name><surname>Mazarakis</surname><given-names>N.D.</given-names></name></person-group><article-title>Transduction patterns of pseudotyped lentiviral vectors in the nervous system</article-title><source>Mol. Ther.</source><year>2004</year><volume>9</volume><fpage>101</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">14741783</pub-id></element-citation></ref><ref id="DDP264C42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>H.</given-names></name><name><surname>Mansfield</surname><given-names>S.G.</given-names></name><name><surname>Bartel</surname><given-names>R.C.</given-names></name><name><surname>Hiriyanna</surname><given-names>S.</given-names></name><name><surname>Mitchell</surname><given-names>L.G.</given-names></name><name><surname>Garcia-Blanco</surname><given-names>M.A.</given-names></name><name><surname>Walsh</surname><given-names>C.E.</given-names></name></person-group><article-title>Phenotype correction of hemophilia A mice by spliceosome-mediated RNA <italic>trans</italic>-splicing</article-title><source>Nat. Med.</source><year>2003</year><volume>9</volume><fpage>1015</fpage><lpage>1019</lpage><pub-id pub-id-type="pmid">12847523</pub-id></element-citation></ref><ref id="DDP264C43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tahara</surname><given-names>M.</given-names></name><name><surname>Pergolizzi</surname><given-names>R.G.</given-names></name><name><surname>Kobayashi</surname><given-names>H.</given-names></name><name><surname>Krause</surname><given-names>A.</given-names></name><name><surname>Luettich</surname><given-names>K.</given-names></name><name><surname>Lesser</surname><given-names>M.L.</given-names></name><name><surname>Crystal</surname><given-names>R.G.</given-names></name></person-group><article-title><italic>Trans</italic>-splicing repair of CD40 ligand deficiency results in naturally regulated correction of a mouse model of hyper-IgM X-linked immunodeficiency</article-title><source>Nat. Med.</source><year>2004</year><volume>10</volume><fpage>835</fpage><lpage>841</lpage><pub-id pub-id-type="pmid">15273748</pub-id></element-citation></ref><ref id="DDP264C44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Luo</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>L.N.</given-names></name><name><surname>Yan</surname><given-names>Z.</given-names></name><name><surname>Zak</surname><given-names>R.</given-names></name><name><surname>Ding</surname><given-names>W.</given-names></name><name><surname>Mansfield</surname><given-names>S.G.</given-names></name><name><surname>Mitchell</surname><given-names>L.G.</given-names></name><name><surname>Engelhardt</surname><given-names>J.F.</given-names></name></person-group><article-title>Spliceosome-mediated RNA <italic>trans</italic>-splicing with recombinant adeno-associated virus partially restores cystic fibrosis transmembrane conductance regulator function to polarized human cystic fibrosis airway epithelial cells</article-title><source>Hum. Gene Ther.</source><year>2005</year><volume>16</volume><fpage>1116</fpage><lpage>1123</lpage><pub-id pub-id-type="pmid">16149910</pub-id></element-citation></ref><ref id="DDP264C45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>I.H.</given-names></name><name><surname>Arora</surname><given-names>N.</given-names></name><name><surname>Huo</surname><given-names>H.</given-names></name><name><surname>Maherali</surname><given-names>N.</given-names></name><name><surname>Ahfeldt</surname><given-names>T.</given-names></name><name><surname>Shimamura</surname><given-names>A.</given-names></name><name><surname>Lensch</surname><given-names>M.W.</given-names></name><name><surname>Cowan</surname><given-names>C.</given-names></name><name><surname>Hochedlinger</surname><given-names>K.</given-names></name><name><surname>Daley</surname><given-names>G.Q.</given-names></name></person-group><article-title>Disease-specific induced pluripotent stem cells</article-title><source>Cell</source><year>2008</year><volume>134</volume><fpage>877</fpage><lpage>886</lpage><pub-id pub-id-type="pmid">18691744</pub-id></element-citation></ref><ref id="DDP264C46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faustino</surname><given-names>N.A.</given-names></name><name><surname>Cooper</surname><given-names>T.A.</given-names></name></person-group><article-title>Pre-mRNA splicing and human disease</article-title><source>Genes Dev.</source><year>2003</year><volume>17</volume><fpage>419</fpage><lpage>437</lpage><pub-id pub-id-type="pmid">12600935</pub-id></element-citation></ref><ref id="DDP264C47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Blanco</surname><given-names>M.A.</given-names></name><name><surname>Baraniak</surname><given-names>A.P.</given-names></name><name><surname>Lasda</surname><given-names>E.L.</given-names></name></person-group><article-title>Alternative splicing in disease and therapy</article-title><source>Nat. Biotechnol.</source><year>2004</year><volume>22</volume><fpage>535</fpage><lpage>546</lpage><pub-id pub-id-type="pmid">15122293</pub-id></element-citation></ref><ref id="DDP264C48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallo</surname><given-names>J.-M.</given-names></name><name><surname>Jin</surname><given-names>P.</given-names></name><name><surname>Thornton</surname><given-names>C.A.</given-names></name><name><surname>Lin</surname><given-names>H.</given-names></name><name><surname>Robertson</surname><given-names>J.</given-names></name><name><surname>D'Souza</surname><given-names>I.</given-names></name><name><surname>Schlaepfer</surname><given-names>W.W.</given-names></name></person-group><article-title>The role of RNA and RNA processing in neurodegeneration</article-title><source>J. Neurosci.</source><year>2005</year><volume>25</volume><fpage>10372</fpage><lpage>10375</lpage><pub-id pub-id-type="pmid">16280575</pub-id></element-citation></ref><ref id="DDP264C49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Licatalosi</surname><given-names>D.D.</given-names></name><name><surname>Darnell</surname><given-names>R.B.</given-names></name></person-group><article-title>Splicing regulation in neurologic disease</article-title><source>Neuron</source><year>2006</year><volume>52</volume><fpage>93</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">17015229</pub-id></element-citation></ref></ref-list></back></article>